Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by Claridge


V.TLT

RE:RE:RE:Instiladrin PH3 data is out

I was not sure if our trial was including high-grade.  It seems so, as...

December 5, 2019

V.TLT

RE:Instiladrin PH3 data is out

Great catch Eoganacht.

December 5, 2019

V.TLT

RE:RE:Ph. 1b P#6 @67 days ...

"Theralase is continuously improving the quality of PDT treatment with...

December 5, 2019

V.TLT

Ph. 1b P#6 @67 days ...

FredGoodwinson ... Great reminder and perspective regarding the fact that P#6...

December 5, 2019

V.TLT

Kodiak Shares Soar on $225 Million Royalty Deal

It gives them a 2.4B$ market valuation now. The stock was trading @7...

December 5, 2019

V.TLT

RE:RE:RE:RE:Results should be clustered

And if they ever decide to publish data before having 20-25 patients, as they...

December 5, 2019

V.TLT

RE:When I met Dr. McFarland in Vancouver,

Gojotv ... 90-day results is one of the 2 primary endpoints (the other one...

December 5, 2019

V.TLT

RE:Bladder Cancer Treatment Enters 'Post-Checkpoint' Era

Choosing Post-Immunotherapy Milowsky noted that if these agents become...

December 5, 2019

V.TLT

Bladder Cancer Treatment Enters 'Post-Checkpoint' Era

Big pharmas still think they can get there with their immuno-therapy strategy...

December 5, 2019

V.TLT

RE:RE:RE:RE:RE:RE:Similar much.... time to tweet @ Bio Optics World

Investclub ... There's many ways to get to the same end-result.  But...

December 4, 2019

V.TLT

RE:RE:RE:Results should be clustered

Don't think you understand how it works.  TLT's main focus is...

December 4, 2019

V.TLT

RE:RE:RE:RE:Similar much.... time to tweet @ Bio Optics World

Investclub ... TLT indeed holds a patent that cover many metals (RU, OS, Ir...

December 4, 2019

V.TLT

RE:RE:Similar much.... time to tweet @ Bio Optics World

Eoganacht ... Nice observation about Dr.Gasser in that study.  There was...

December 4, 2019

V.TLT

Destroying cancer at the speed of light

EnriquesSuave ... Nice catch.  Thanks for sharing. Have you noticed...

December 4, 2019

V.TLT

RE:RE:RE:RE:RE:RE:RE:How much study drug do we need?

Hempdoc ... Good input too.  Thanks for sharing. ______________________...

December 3, 2019

V.TLT

Fig. 3 - Keytruda's Time to CR and time to recurences

Take a look at Fig. 3 in this link related to the Feb. 2019 The Barron's...

December 3, 2019

V.TLT

RE:RE:RE:RE:RE:RE:How much study drug do we need?

EnriqueSuave ... That's an interesting example.  Thanks for sharing....

December 3, 2019

V.TLT

RE:RE:RE:RE:How much study drug do we need?

But you would still need shelf life certifications, if we take the example of...

December 3, 2019

V.TLT

RE:RE:RE:How much study drug do we need?

We call this not putting all your eggs in the same basket.  Especially...

December 3, 2019

V.TLT

RE:RE:How much study drug do we need?

TLD-1433 = SAFC (subsidiary of Sigma-Aldrich, which is a subsidiairy of Merck...

December 3, 2019